Skip to content

Clinical evaluation of VAYU KEELAGA ILAKAM (Internal) with ERUKKATHY THYLAM (External)in the treatment of MUDAKKU VATHAM .

Evaluation of safety and therapeutic efficacy of VAYU KEELAGA ILAKAM (Internal medicine) with ERUKKATHY THYLAM (External medicine) in the treatment of UTHIRA VATHA SURONITHAM(Rheumatoid arthritis). - Uthira Vatha Suronitham (Rheumatoid arthritis)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/013541
Enrollment
30
Registered
2018-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- UTHIRA VATHA SURONITHAM (Rheumatoid arthritis)

Interventions

Intervention1: Nil: Nil Control Intervention1: Vayu Keelaga Ilakam (Internal) Erukkathy thylam (External): vayu keelaga ilakam ,Kottai pakkalavu (5gm) will be administrated orally,after food twice a d

Sponsors

Ayothidoss Pandithar Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Insidious onset of polyarthritis with pain in the joints,Prolonged morning stiffness ( for 6 weeks or longer),Swelling of multiple involved joints (for 6 weeks or longer),Slow progressive signs of inflammation ,e.g.pain,Tenderness,warmth,eythymatous > 6 weeks,Symmetrical joints involvement,Swelling especially in inter phalangeal joints,RA factor positive or Negative,Patients willing to admission in IPD or willing to attend OPD,Patients willing to undergo Radiological investigations and other laboratory investigations,Patient willing to sign the informed consent stating that she/he will consciously stick to the treatment during 48 days but can opt out the trial his/her own conscious discretion.

Exclusion criteria

Exclusion criteria: Pregnancy and lactation,Tubercular arthritis,Any other serious systemic illness like Cancer,Cardiac Diseases,osteoarthritis,Psoriatic arthritis,Gouty arthritis,Diabetic Mellitus,Hypertension,Characteristic deformities of hands ans feet in Rheumatoid arthritis,Systemic complication of Rheumatoid arthritis.

Design outcomes

Primary

MeasureTime frame
Assessment of pain will be Universal pain Assessment Scale.Other clinical signs and symptoms will be assessed by gradation method.Timepoint: After the 48 days of treatment , pain will be assessed by Universal pain Assessment Scale.Other clinical signs and symptoms will be assessed by gradation method.

Secondary

MeasureTime frame
secondary outcome will be assessed by comparing the parameters ,before and after treatment (laboratory investigations such as RA factor,ESR,CRP,ASO titre ,Anti-CCP,X-ray affected joints AP and Lateral view),reduction of clinical symptoms.Timepoint: 45 days

Countries

India

Contacts

Public ContactDrHNalini Sofia

national Institute of Siddha

dr.kmvm@gmail.com9444249798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026